Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Antibody drug conjugate

EU flag

AbbVie’s hep C combo gets priority review in Europe

EMA to fast track drug for use in hard-to-treat genotype 1 strain of HCV

- PMLiVE

NICE rejects Roche’s Kadcyla as “unaffordable”

Cancer drug unable to justify £90,000 price tag

Novartis building

Novartis pays $16bn for GSK’s oncology portfolio

Swiss company strikes series of deals, including one to step away from vaccines

- PMLiVE

Lilly’s stomach cancer drug cleared by FDA

Cyramza is tipped to reach blockbuster status depending on approvals

- PMLiVE

BioAlliance and Topotarget merge to focus on rare cancers

French and Danish firms combine to develop orphan oncology drugs

- PMLiVE

Oral hepatitis C regimens tackle advanced liver disease

 New data released at the International Liver Congress by AbbVie, Merck & Co and Gilead

- PMLiVE

UK cancer awards programme launches

QiC Oncology 2014  announced at ABPI Annual Conference

- PMLiVE

Humira still the biggest pharma brand

The industry’s best-selling products revealed in the latest PMLiVE Top Pharma List figures

- PMLiVE

AbbVie drops legal case against EMA

Accepts publication of new set of redacted Humira data

- PMLiVE

Glioblastomas – a personalised future?

Despite some recent advances treatment remains palliative

- PMLiVE

Lilly thrown a lifeline on US Alimta patent

Court backs protection from generics until 2022

- PMLiVE

GSK halts bid for Votrient maintenance use

Pulls European application for indication in advanced ovarian cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links